Update on mGlu4 modulator patents: 2017 to present.

Area of Science:

• Neuroscience
• Pharmacology
• Drug Discovery

Background:

• Metabotropic glutamate receptor 4 (mGluR4) plays a role in neurotransmitter release and synaptic plasticity.
• Dysregulation of mGluR4 is linked to neurodegenerative disorders, psychiatric conditions, and other brain disorders.
• mGluR4 is an emerging therapeutic target for conditions such as Parkinson's disease, multiple sclerosis, and chronic pain.

Purpose of the Study:

• To review patents and literature on mGluR4 positive allosteric modulators (PAMs) from 2017 to 2024.
• To summarize key exemplified compounds, structure-activity relationships (SAR), and biological data.
• To discuss key findings and future directions for mGluR4 PAM development.

Main Methods:

• Literature and patent searches using SciFinder, Google Patents, and PubMed.
• Analysis of exemplified compounds, SAR, and biological data from retrieved sources.
• Synthesis of findings to assess the current state and future prospects of mGluR4 PAMs.

Main Results:

• Several mGluR4 PAMs have been exemplified in patents and literature.
• Two compounds have progressed to early-stage clinical trials.
• One clinical trial (Prexton Therapeutics) failed due to efficacy issues; results from another (Appello Pharmaceuticals) are pending.

Conclusions:

• mGluR4 PAMs represent a promising therapeutic strategy for various neurological and psychiatric conditions.
• The outcome of ongoing clinical trials will be critical in determining the future of mGluR4 PAMs in drug development.
• Further research and development are needed to overcome efficacy challenges and advance mGluR4-targeted therapies.